Research programme: influenza virus vaccine liposomal - Xenetic BiosciencesAlternative Names: Liposomal influenza vaccine - Xenetic Biosciences
Latest Information Update: 27 Nov 2014
At a glance
- Originator Lipoxen Technologies
- Developer Xenetic Biosciences
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 27 Nov 2014 No development reported - Preclinical for Influenza virus infections in USA (Parenteral)
- 08 Sep 2011 Lipoxen is now called Xenetic Biosciences